Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.

NCT02918162 is registered in ClinicalTrials.gov with Gulam Manji as lead sponsor.

NCT NCT02918162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02918162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.
Lead sponsor
Gulam Manji
Phase
Phase 2
Overall status
Completed
Start date
November 25, 2017
Completion date
February 28, 2023
Enrollment
49 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, gastric cancer